Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis
- PMID: 32165208
- DOI: 10.1053/j.gastro.2020.03.007
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis
Abstract
Background & aims: Biomarkers are needed to identify patients at risk for development of inflammatory bowel diseases. We aimed to identify serum biomarkers of Crohn's disease and ulcerative colitis that can be detected and quantified before diagnosis.
Methods: We obtained serum samples from patients archived before a diagnosis of Crohn's disease (n = 200) or ulcerative colitis (n = 199), as well as from 200 healthy individuals (controls), collected from 1998 through 2013 as part of the US Defense Medical Surveillance System. We measured levels of antibodies against microbes (anti-Saccharomyces cerevisiae IgA or IgG, anti-Escherichiacoli outer membrane porin C, anti-CBir1, anti-flagellin 2, anti-flagellin X, and perinuclear anti-neutrophil cytoplasmic antibodies) and 1129 proteins in each sample. We then used functional principal component analysis to derive the time-varying trajectory for each marker, which then was used in a multivariate model to predict disease status. Predictive performances at different prediagnosis timepoints were evaluated using area under the receiver operating characteristic curves (AUROCs). Biological pathways that were up-regulated in serum from patients with Crohn's disease were identified based on changes in protein abundance at different time periods preceding diagnosis.
Results: We identified a panel of 51 protein biomarkers that were predictive of Crohn's disease within 5 years with an AUROC of 0.76 and a diagnosis within 1 year with an AUROC of 0.87. Based on the proteins included in the panel, imminent development of CD was associated with changes in the complement cascade, lysosomes, innate immune response, and glycosaminoglycan metabolism. Serum antibodies and proteins identified patients who received a diagnosis of ulcerative colitis within 5 years with an AUROC of only 0.56 and within 1 year with an AUROC of 0.72.
Conclusions: We identified a panel of serum antibodies and proteins that were predictive of patients who will receive a diagnosis of Crohn's disease within 5 years with high accuracy. By contrast we did not identify biomarkers associated with future diagnosis of ulcerative colitis.
Keywords: ASCA; IBD; pANCA; prognostic.
Copyright © 2020 AGA Institute. All rights reserved.
Comment in
-
New Biomarkers for Crohn's Disease.Gastroenterology. 2020 Jul;159(1):30-32. doi: 10.1053/j.gastro.2020.04.056. Epub 2020 Apr 29. Gastroenterology. 2020. PMID: 32360659 No abstract available.
-
Preclinical Inflammatory Bowel Disease: Back to the Future.Gastroenterology. 2021 Jan;160(1):475-476. doi: 10.1053/j.gastro.2020.04.081. Epub 2020 Sep 12. Gastroenterology. 2021. PMID: 32931786 No abstract available.
-
Reply.Gastroenterology. 2021 Jan;160(1):476-477. doi: 10.1053/j.gastro.2020.10.045. Epub 2020 Nov 4. Gastroenterology. 2021. PMID: 33159925 No abstract available.
Similar articles
-
Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.Am J Gastroenterol. 2004 Nov;99(11):2235-41. doi: 10.1111/j.1572-0241.2004.40369.x. Am J Gastroenterol. 2004. PMID: 15555007
-
Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.Gut. 1998 Jun;42(6):788-91. doi: 10.1136/gut.42.6.788. Gut. 1998. PMID: 9691915 Free PMC article.
-
Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course.J Crohns Colitis. 2015 Jun;9(6):445-51. doi: 10.1093/ecco-jcc/jjv063. Epub 2015 Apr 19. J Crohns Colitis. 2015. PMID: 25895876
-
[Relevance of serologic studies in inflammatory bowel diseases].Orv Hetil. 2007 May 13;148(19):887-96. doi: 10.1556/OH.2007.28064. Orv Hetil. 2007. PMID: 17478404 Review. Hungarian.
-
Advances in clinical laboratory tests for inflammatory bowel disease.Clin Chim Acta. 2003 Sep;335(1-2):9-20. doi: 10.1016/s0009-8981(03)00286-9. Clin Chim Acta. 2003. PMID: 12927679 Review.
Cited by
-
Diagnosis and natural history of preclinical and early inflammatory bowel disease.Ann Gastroenterol. 2020 Sep-Oct;33(5):443-452. doi: 10.20524/aog.2020.0508. Epub 2020 Jun 22. Ann Gastroenterol. 2020. PMID: 32879589 Free PMC article. Review.
-
Patients With Inflammatory Bowel Disease Show IgG Immune Responses Towards Specific Intestinal Bacterial Genera.Front Immunol. 2022 May 25;13:842911. doi: 10.3389/fimmu.2022.842911. eCollection 2022. Front Immunol. 2022. PMID: 35693832 Free PMC article.
-
Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohn's Disease.Gastroenterology. 2022 Sep;163(3):659-670. doi: 10.1053/j.gastro.2022.05.029. Epub 2022 May 24. Gastroenterology. 2022. PMID: 35623454 Free PMC article.
-
New pattern of individualized management of chronic diseases: focusing on inflammatory bowel diseases and looking to the future.Front Med (Lausanne). 2023 May 10;10:1186143. doi: 10.3389/fmed.2023.1186143. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37265491 Free PMC article. Review.
-
Fungal plasma biomarkers in patients admitted for inpatient treatment of alcohol use disorder.Alcohol Clin Exp Res (Hoboken). 2023 Aug;47(8):1582-1589. doi: 10.1111/acer.15140. Epub 2023 Jul 10. Alcohol Clin Exp Res (Hoboken). 2023. PMID: 37364901 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous